Member Info for Bladderman

Sorry 960K tests per month would give £58M - £2M admin costs is £56M profit per year. MCap £35M and 8M cash already. Even 480k tests per month would give £28M-2M so £26M per year plus £8M cash, no debt therefore would equal our current market cap!!! That's how cheap we are.

Of course 1.9M test per month would male us £112M profit per annum lol.

What about the US military contract. Hep C test kit WHO approval and neonatal baby deafness test venture with IHC.

Okay Saint - so that for just one million sample tests a year we are looking at £60M profit per year. Current MCap £35M.

GDR can make 10k tests per hour so require 100 hours of production a month to make 900k

Therefore 10k test production for 3 h a day every day of the month gives 900k tests which equates to a £40M clear profit a year to GDR

With 8 billion in the world and considering the rising global pandemic do we think we could sell a million tests for a million people a year of our superior product a year - I do - minimum!!! That's why I added this morning

So 40% of a £900 superior test so £400 profit per unit (a 96 well plate)

So even 96 000 sample tests (a 1000 plate units) is £400k clear profit to GDR.
So 960k samples to be tested is £4M clear profit. Over a year that is £40M clear profit to test 960k people per month.

We are valued at £35M with 22% cash alone.

Hahahahah

Yes flyingmachine - a house keeping gene.

No offence but NCYT's product is a bit inferior

Seems to have settled after some wild selling days. Still can't believe the fall. Difficult to not hold stock at this stage of proceedings

Have we reached the bottom?? Possible intraday reversal in play

Good post Saint and highly valid!

Cytiva on board and confirmed the 3 milestone test before any other form of approval was sought - nice n robust

Cheers Shaa - it has been well documented that a finish above 0.35p is very bullish here and signals a break out.

Very positive news imminent.

Finance sorted. Shares forward sold - what's not to like

Patiently waiting for the imminent approvals.

COVID mutates too much for a vaccine to be effective. Also rushing this through is not the answer

Anglo want to buy the assets

9

Anglo worth £20 billion within the exclusivity period if they want it will complete a 'commercial tranaction'. In other words have to exclusive option to purchase

Can sell at 2.8p but can't buy at 2.8p Ask

.

Anglo exclusivity agreement currently valued at £8M more than it was before news. Can see why it's 3 to 1

Stock under 3p isn't available for long....

Why is that not surprising! 4p plus by tomorrow morning at this rate

Anglo - almost as big as it gets